SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of ShareholdersAccesswire • 10/02/24
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTHBusiness Wire • 08/26/24
RFL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Rafael Holdings, Inc. Is Fair to ShareholdersBusiness Wire • 08/22/24
Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 IntermediariesBusiness Wire • 08/22/24
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger AgreementBusiness Wire • 08/22/24
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger AgreementGlobeNewsWire • 08/22/24
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsGlobeNewsWire • 10/30/23
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.Business Wire • 08/02/23
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 06/13/23
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private PlacementBusiness Wire • 06/05/23
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)Business Wire • 05/02/23
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development ActivitiesGlobeNewsWire • 11/15/22
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic CancerGlobeNewsWire • 09/28/22
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public GarageGlobeNewsWire • 08/23/22
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.GlobeNewsWire • 07/06/22
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATEGlobeNewsWire • 06/16/22
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma CatabolismGlobeNewsWire • 06/16/22